Renal Cell Carcinoma
📧 Sign up to get email alerts when something new happens for Renal Cell Carcinoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-02-13Clinical Trial Update: Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
This ClinicalTrials.gov entry describes a study by A2 Biotherapeutics evaluating HLA LOH analysis and apheresis for CAR-T cell manufacturing…
-
CLINICAL_TRIALS trial_result · 2026-02-13Clinical Trial Update: A Phase I Clinical Study to Evaluate the PK Profile, Efficacy, Safety and Immunogenicity of HLX17 vs. Keytruda® in Multiple Resected Solid Tumors [Phase 1]
Phase I trial comparing HLX17 to Keytruda in multiple solid tumors to evaluate pharmacokinetics, preliminary efficacy, safety, and immunogen…
-
CLINICAL_TRIALS research · 2026-02-12Clinical Trial Update: Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study [Phase 2]
A Phase 2 trial (The Knight SHIFT Study) is comparing morning versus afternoon administration of immunotherapy for advanced or metastatic so…
-
CLINICAL_TRIALS trial_result · 2026-02-12Clinical Trial Update: Circulating and Urinary Exosomal miRNA in Advanced Kidney Cancer (EXO-RENAL1) [NA]
This clinical trial update reports the completed status of the EXO-RENAL1 study evaluating circulating and urinary exosomal miRNA in advance…
-
CLINICAL_TRIALS research · 2026-02-12Clinical Trial Update: A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participants With Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma [Phase 2]
An active Phase 2 Roche-sponsored trial is evaluating combinations of an immune checkpoint inhibitor with Axitinib in untreated locally adva…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2026-02-12Clinical Trial Update: Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A) [Phase 1, Phase 2]
Clinical trial update for MK-3475-03A, a Phase 1/2 study of immune and targeted therapy combinations in first-line renal cell carcinoma, spo…
-
CLINICAL_TRIALS research · 2026-02-11Clinical Trial Update: Outcomes Database to prospectivelY aSSEss the Changing TherapY Landscape in Renal Cell Carcinoma
This clinical trial update describes a prospective outcomes database to assess how the therapy landscape for Metastatic renal cell carcinoma…
-
CLINICAL_TRIALS research · 2026-02-11Clinical Trial Update: Advanced Renal Cell Cancer Combination ImmunoThErapy Clinical Trial [Phase 2]
A Phase 2 clinical trial of a combination immunotherapy for advanced renal cell carcinoma is currently suspended.
-
CLINICAL_TRIALS research · 2026-02-10Clinical Trial Update: Analyzing Clinical Outcomes and Genomic Data of American Indian Patient Population
This clinical trial update analyzes clinical outcomes and genomic data from American Indian patients across several cancer indications, with…
-
CLINICAL_TRIALS research · 2026-02-09Clinical Trial Update: P-MUC1C-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Advanced or Metastatic Solid Tumors [Phase 1]
Phase 1 trial update of P-MUC1C-ALLO1, an allogeneic CAR-T cell therapy, being studied in advanced or metastatic solid tumors. The study is …
-
CLINICAL_TRIALS research · 2026-02-09Clinical Trial Update: A Study of Ward Admissions for Haematuria
This clinical trial update shows a study on ward admissions for patients with haematuria that is currently recruiting.
-
CLINICAL_TRIALS trial_result · 2026-02-09Clinical Trial Update: A Clinical Gene Therapy Study With Hematopoietic Stem Cells for the Treatment, With Single Dose of Temferon, of Patients Suffering From Metastatic Renal Cell Carcinoma [Phase 1, Phase 2]
A Phase 1/2 clinical trial evaluating Temferon, a hematopoietic stem cell gene therapy, for metastatic renal cell carcinoma (clear cell RCC)…
-
EMA approval · 2026-02-06EMA Authorised: Alymsys (bevacizumab) — Mabxience Research SL
The EMA authorised Alymsys, a bevacizumab biosimilar from Mabxience Research SL. It is approved for multiple cancer indications including co…
-
CLINICAL_TRIALS trial_result · 2026-02-06Clinical Trial Update: A Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory Solid Tumors and Lymphomas [Phase 1]
Phase 1 study evaluating CD45RA+ depleted haploidentical stem cell transplantation in children with relapsed or refractory solid tumors and …
-
EMA approval · 2026-02-05EMA Authorised: Avzivi (bevacizumab) — FGK Representative Service GmbH
EMA authorised Avzivi (bevacizumab) for multiple indications including colorectal cancer, non-small cell lung cancer, renal cell carcinoma, …
-
CLINICAL_TRIALS research · 2026-02-05Clinical Trial Update: Spinal Morphine or Intravenous Lidocaine in Robot-assisted Upper Urologic Surgery [Phase 3]
A Phase 3 trial comparing spinal morphine with intravenous lidocaine for anesthesia in robot-assisted upper urologic surgery is currently re…
-
CLINICAL_TRIALS research · 2026-02-03Clinical Trial Update: Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer [Phase 3]
This is a Phase 3 clinical trial update indicating plans to add a biotherapy or placebo to standard treatment for advanced or metastatic ren…
-
CLINICAL_TRIALS research · 2026-02-03Clinical Trial Update: Investigation of Lymph Node Biology in Kidney Cancer [NA]
A Yale University-sponsored clinical trial investigating lymph node biology in renal cell carcinoma is currently recruiting.
-
CLINICAL_TRIALS research · 2026-02-03Clinical Trial Update: NeoVax Plus Ipilimumab in Renal Cell Carcinoma [Phase 1]
Phase 1 trial update testing NeoVax, a personalized neoantigen vaccine, in combination with ipilimumab for renal cell carcinoma; the study i…
-
CLINICAL_TRIALS research · 2026-01-30Clinical Trial Update: Sequential Two-agent Assessment in Renal Cell Carcinoma Therapy: The START Trial [Phase 2]
This clinical trial update discusses the START trial, a Phase 2 study assessing sequential two-agent therapy for renal cell carcinoma. The s…
-
CLINICAL_TRIALS trial_result · 2026-01-29Clinical Trial Update: UCDCC#272: IL-2, Radiotherapy, and Pembrolizumab in Patients Refractory to Checkpoint Blockade [Phase 1, Phase 2]
Phase 1/2 trial evaluating interleukin-2 with radiotherapy and pembrolizumab in patients refractory to checkpoint blockade; results have bee…
-
CLINICAL_TRIALS research · 2026-01-29Clinical Trial Update: Memory-like Natural Killer (NK) Cell Therapy in Patients With Renal Cell Carcinoma or Urothelial Carcinoma [EARLY_Phase 1]
This early-phase trial is evaluating memory-like natural killer (NK) cell therapy in patients with renal cell carcinoma and urothelial carci…
-
EMA approval · 2026-01-28EMA Authorised: Abevmy (bevacizumab) — Biosimilar Collaborations Ireland Limited
EMA authorised Abevmy (bevacizumab) as a biosimilar. It is approved for several cancer indications including colorectal, breast, ovarian, fa…
-
EMA approval · 2026-01-28EMA Authorised: Vegzelma (bevacizumab) — Celltrion Healthcare Hungary Kft.
EMA authorised Vegzelma, a bevacizumab biosimilar from Celltrion Healthcare Hungary Kft., for multiple cancers including colorectal, breast,…
-
EMA approval · 2026-01-28EMA Authorised: Aybintio (bevacizumab) — Samsung Bioepis NL B.V.
The EMA authorised Aybintio, a bevacizumab biosimilar from Samsung Bioepis NL B.V., for multiple cancer indications including colorectal, br…